Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC).
The DOI matches its Crossref record.
Abstract
103 Background: BRAF V600E mutations occur in 5–10% of mCRC and confer a poor prognosis. Unlike BRAFm melanoma, BRAF and MEK inhibitors have minimal activity in BRAFm mCRC. Preclinical data suggest that combined inhibition of the EGFR and MAPK pathways is required to maximally inhibit growth of BRAFm mCRC. This study evaluates the activity of the combination of P with D and/or T in BRAFm mCRC. Methods: Eligible pts with BRAFm mCRC received doublet, D+P or T+P, or triplet, D+T+P. Results: Doublet (D+P): 20 pts received the full doublet dose (D 150mg twice daily [BID] + P 6mg/kg every 2 weeks [Q2W]). Triplet: 35 pts received D+T+P including 24 pts that received full triplet dose (D 150mg BID + T 2mg once daily [QD] + P 6mg/kg Q2W). No dose-limiting toxicities were observed. As of October 20, 2014, the most common adverse events were dermatitis acneiform (Grade [G] 1/2 55%) and fatigue (G 1/2 45%) for D+P, and diarrhea (G1/2 60%, G3 9%) and dermatitis acneiform (G1/2 47%; G3 9%) for triplet. The confirmed response rate for D+P was 10% and for D+T+P was 26% (Table 1). Treatment with either regimen reduced levels of pERK in on-treatment biopsies relative to pre-dose biopsies (median reduction D+P 23%; D+T+P 54%). Pts are currently being enrolled to T+P. Updated results including progression-free survival and duration of response will be presented. Conclusions: Encouraging clinical activity with acceptable tolerability is seen with the triplet D+T+P in BRAFm mCRC. Clinical trial information: NCT01750918.Investigator–assessed best response with confirmation (RECIST 1.1). D 150 mg BID+ P 6mg/kg Q2W N = 20 D 150 mg BID, T 1.5 mg QD, P 4.8 mg/kg Q2W N = 3 D 150 mg BID, T 2 mg QD, P 4.8 mg/kg Q2W N = 4 D 150 mg BID, T 1.5 mg QD, P 6 mg/kg Q2W N = 4 D 150 mg BID, T 2 mg QD, P 6 mg/kg Q2W N=24 D+T+P Total N = 35 Complete response, n (%) 1 (5) 0 1 (25) 0 0 1 (3) Partial response, n (%) 1 (5) 2 (67) 1 (25) 0 5 (21) 8 (23) Stable disease, n (%) 16 (80) 1 (33) 2 (50) 2 (50) 15 (63) 20 (57) Progressive disease, n (%) 2 (10) 0 0 2 (50) 3 (13) 5 (14) Not evaluable, n (%) 0 0 0 0 1 (4) 1 (3) Response rate (CR+PR), n (%) 2 (10) 2 (67) 2 (50) 0 5 (21) 9 (26) 95% confidence interval, % 1.2–31.7 9.4–99.2 6.8–93.2 0.0–60.2 7.1–42.2 12.5–43.3
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Corcoran, R. B., Atreya, C. E., Falchook, G. S., Kwak, E. L., Ryan, D. P., Bendell, J. C., Hamid, O., Messersmith, W. A., Daud, A., Kurzrock, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.2471 · Cited by 507
Self-citationCombine and conquer: challenges for targeted therapy combinations in early phase trials
Lopez, J. S., & Banerji, U. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.96 · Cited by 394
Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer
Russo, M., Siravegna, G., Blaszkowsky, L. S., Corti, G., Crisafulli, G., Ahronian, L. G., Mussolin, B., Kwak, E. L., Buscarino, M., Lazzari, L., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1283 · Cited by 405
Self-citationBRAF mutant colorectal cancer: prognosis, treatment, and new perspectives
Sanz-Garcia, E., Argiles, G., Elez, E., & Tabernero, J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx401 · Cited by 302
Self-citationvan Geel, R. M. J. M., Tabernero, J., Elez, E., Bendell, J. C., Spreafico, A., Schuler, M., Yoshino, T., Delord, J.-P., Yamada, Y., Lolkema, M. P., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0795 · Cited by 232
Self-citation
Metadata
- Authors
- Atreya, C. E., Van Cutsem, E., Bendell, J. C., Andre, T., Schellens, J. H. M., Gordon, M. S., McRee, A. J., O'Dwyer, P. J., Muro, K., Tabernero, J., van Geel, R., Sidhu, R., Greger, J. G., Rangwala, F. A., Motwani, M., Wu, Y., Orford, K. W., & Corcoran, R. B.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-05-20
- Volume
- 33
- Issue
- 15_suppl
- Pages
- 103-103
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2599487961
- Cited by
- 62
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC). https://app.cochat.ai/papers/10.1200/jco.2015.33.15_suppl.103
- The paper
- Atreya, C. E., Van Cutsem, E., Bendell, J. C., Andre, T., Schellens, J. H. M., Gordon, M. S., McRee, A. J., O'Dwyer, P. J., Muro, K., Tabernero, J., van Geel, R., Sidhu, R., Greger, J. G., Rangwala, F. A., Motwani, M., Wu, Y., Orford, K. W., & Corcoran, R. B. (2015). Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. https://doi.org/10.1200/jco.2015.33.15_suppl.103
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.